Total Payments
$608.26
2020 Payments
$60.25
Companies
5
Transactions
25
Medicare Patients
3,061
Medicare Billing
$611,396
Payment Breakdown by Category
Food & Beverage$420.02 (69.1%)
Education$188.24 (30.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $420.02 | 22 | 69.1% |
| Education | $188.24 | 3 | 30.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Astellas Pharma US Inc | $188.24 | 3 | $0 (2020) |
| The Medicines Company | $177.35 | 13 | $0 (2018) |
| Theravance Biopharma, Inc. | $118.30 | 1 | $0 (2018) |
| Merck Sharp & Dohme Corporation | $110.36 | 7 | $0 (2017) |
| Gilead Sciences, Inc. | $14.01 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2020 | $60.25 | 1 | Astellas Pharma US Inc ($60.25) |
| 2019 | $99.00 | 1 | Astellas Pharma US Inc ($99.00) |
| 2018 | $173.30 | 4 | Theravance Biopharma, Inc. ($118.30) |
| 2017 | $275.71 | 19 | The Medicines Company ($165.35) |
All Payment Transactions
25 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/28/2020 | Astellas Pharma US Inc | — | Education | In-kind items and services | $60.25 | General |
| 09/09/2019 | Astellas Pharma US Inc | — | Education | In-kind items and services | $99.00 | General |
| 11/01/2018 | Theravance Biopharma, Inc. | VIBATIV (Drug) | Food and Beverage | In-kind items and services | $118.30 | General |
| Category: Infectious Disease | ||||||
| 09/21/2018 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $14.01 | General |
| 09/14/2018 | Astellas Pharma US Inc | — | Education | In-kind items and services | $28.99 | General |
| 01/04/2018 | The Medicines Company | VABOMERE (Drug) | Food and Beverage | In-kind items and services | $12.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/14/2017 | The Medicines Company | MINOCIN IV (Drug), ORBACTIV | Food and Beverage | In-kind items and services | $11.54 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 08/24/2017 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug), SIVEXTRO | Food and Beverage | In-kind items and services | $12.13 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 07/28/2017 | The Medicines Company | MINOCIN IV (Drug), ORBACTIV | Food and Beverage | In-kind items and services | $14.94 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 06/12/2017 | The Medicines Company | ORBACTIV (Drug) | Food and Beverage | In-kind items and services | $10.56 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/27/2017 | The Medicines Company | MINOCIN IV (Drug) | Food and Beverage | In-kind items and services | $12.40 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/26/2017 | The Medicines Company | ORBACTIV (Drug) | Food and Beverage | In-kind items and services | $14.16 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/17/2017 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $15.34 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/10/2017 | Merck Sharp & Dohme Corporation | CUBICIN RF (Drug), ZERBAXA | Food and Beverage | In-kind items and services | $13.79 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/08/2017 | The Medicines Company | ORBACTIV (Drug) | Food and Beverage | In-kind items and services | $15.64 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/04/2017 | The Medicines Company | ORBACTIV (Drug), MINOCIN IV | Food and Beverage | In-kind items and services | $14.60 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 04/28/2017 | The Medicines Company | MINOCIN IV (Drug), ORBACTIV | Food and Beverage | In-kind items and services | $9.61 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 04/27/2017 | The Medicines Company | ORBACTIV (Drug), MINOCIN IV | Food and Beverage | In-kind items and services | $11.07 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 04/13/2017 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $15.87 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 03/24/2017 | Merck Sharp & Dohme Corporation | — | Food and Beverage | In-kind items and services | $20.14 | General |
| 03/23/2017 | Merck Sharp & Dohme Corporation | — | Food and Beverage | In-kind items and services | $17.83 | General |
| 03/17/2017 | The Medicines Company | ORBACTIV (Drug) | Food and Beverage | In-kind items and services | $15.82 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 02/24/2017 | The Medicines Company | MINOCIN IV (Drug), ORBACTIV | Food and Beverage | In-kind items and services | $17.42 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/27/2017 | The Medicines Company | MINOCIN IV (Drug), ORBACTIV | Food and Beverage | In-kind items and services | $17.59 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/11/2017 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $15.26 | General |
| Category: INFECTIOUS DISEASE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 269 | 625 | $323,937 | $44,721 |
| 2022 | 2 | 111 | 390 | $88,422 | $23,600 |
| 2021 | 15 | 838 | 2,657 | $442,998 | $132,451 |
| 2020 | 20 | 1,843 | 180,878 | $1.4M | $410,624 |
Total Patients
3,061
Total Services
184,550
Medicare Billing
$611,396
Procedure Codes
46
All Medicare Procedures & Services
46 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| G0407 | Follow-up inpatient consultation, intermediate, physicians typically spend 25 minutes communicating with the patient via telehealth | Facility | 2023 | 78 | 300 | $137,700 | $17,432 | 12.7% |
| G0408 | Follow-up inpatient consultation, complex, physicians typically spend 35 minutes communicating with the patient via telehealth | Facility | 2023 | 57 | 114 | $75,240 | $9,700 | 12.9% |
| G0426 | Telehealth consultation, emergency department or initial inpatient, typically 50 minutes communicating with the patient via telehealth | Facility | 2023 | 52 | 58 | $50,344 | $5,981 | 11.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 43 | 109 | $19,656 | $5,684 | 28.9% |
| G0427 | Telehealth consultation, emergency department or initial inpatient, typically 70 minutes or more communicating with the patient via telehealth | Facility | 2023 | 26 | 27 | $34,533 | $3,997 | 11.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 13 | 17 | $6,464 | $1,926 | 29.8% |
| G0407 | Follow-up inpatient consultation, intermediate, physicians typically spend 25 minutes communicating with the patient via telehealth | Facility | 2022 | 71 | 350 | $72,961 | $19,633 | 26.9% |
| G0426 | Telehealth consultation, emergency department or initial inpatient, typically 50 minutes communicating with the patient via telehealth | Facility | 2022 | 40 | 40 | $15,461 | $3,967 | 25.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 187 | 363 | $107,085 | $30,481 | 28.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 159 | 163 | $61,125 | $26,484 | 43.3% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2021 | 34 | 337 | $75,825 | $19,155 | 25.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 57 | 151 | $37,750 | $14,651 | 38.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 175 | 228 | $58,235 | $13,239 | 22.7% |
| G0407 | Follow-up inpatient consultation, intermediate, physicians typically spend 25 minutes communicating with the patient via telehealth | Facility | 2021 | 42 | 205 | $30,451 | $11,630 | 38.2% |
| 99496 | Transitional care management services, highly complexity, requiring face-to-face visits within 7 days of discharge | Office | 2021 | 20 | 20 | $9,000 | $4,479 | 49.8% |
| G0426 | Telehealth consultation, emergency department or initial inpatient, typically 50 minutes communicating with the patient via telehealth | Facility | 2021 | 37 | 38 | $10,698 | $4,081 | 38.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 20 | 22 | $6,820 | $2,474 | 36.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 16 | 16 | $6,000 | $2,428 | 40.5% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 11 | 11 | $4,125 | $1,432 | 34.7% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 14 | 14 | $3,990 | $863.41 | 21.6% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2021 | 11 | 11 | $935.00 | $467.06 | 50.0% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2021 | 14 | 732 | $25,620 | $323.33 | 1.3% |
| J7050 | Infusion, normal saline solution, 250 cc | Office | 2021 | 26 | 316 | $4,740 | $172.86 | 3.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 15 | 30 | $600.00 | $90.00 | 15.0% |
| J0875 | Injection, dalbavancin, 5 mg | Office | 2020 | 28 | 9,000 | $216,000 | $108,861 | 50.4% |
About Dr. Annette Artau, MD
Dr. Annette Artau, MD is a Infectious Disease healthcare provider based in Sarasota, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/10/2013. The National Provider Identifier (NPI) number assigned to this provider is 1639512429.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Annette Artau, MD has received a total of $608.26 in payments from pharmaceutical and medical device companies, with $60.25 received in 2020. These payments were reported across 25 transactions from 5 companies. The most common payment nature is "Food and Beverage" ($420.02).
As a Medicare-enrolled provider, Artau has provided services to 3,061 Medicare beneficiaries, totaling 184,550 services with total Medicare billing of $611,396. Data is available for 4 years (2020–2023), covering 46 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Sarasota, FL
- Active Since 04/10/2013
- Last Updated 10/14/2019
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1639512429
Products in Payments
- VIBATIV (Drug) $118.30
- MINOCIN IV (Drug) $83.50
- ORBACTIV (Drug) $81.85
- ZERBAXA (Drug) $58.60
- CUBICIN RF (Drug) $13.79
- VABOMERE (Drug) $12.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Sarasota
Dr. Lavinia Suciu, M.d, M.D
Infectious Disease — Payments: $6,987
Infectious Disease $6,987
Andrew Krinsky, Md, MD
Infectious Disease — Payments: $6,044
Infectious Disease $6,044
Manuel Gordillo, Md, MD
Infectious Disease — Payments: $3,558
Infectious Disease $3,558
Rishi Bhattacharyya, Md, MD
Infectious Disease — Payments: $2,529
Infectious Disease $2,529
Natan Kraitman, M.d, M.D
Infectious Disease — Payments: $1,877
Infectious Disease $1,877
Sudha Tallapragada, Md, MD
Infectious Disease — Payments: $1,461
Infectious Disease $1,461